Anebulo Pharmaceuticals Announces Interim Data For ANEB-001 From Part B Of Its Phase 2 Clinical Trial For Acute Cannabinoid Intoxication; Says Lower Doses Of ANEB-001 Reduced The Negative Effects Of Higher Doses Of THC
Lower doses of ANEB-001 reduced the negative effects of higher doses of THC
Currently exploring delayed dosing to better understand real-world conditions
AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals,
